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ABSTRACT 
 
Targeted drug delivery has been the major topic in drug formulation and delivery. As 
nanomedicine emerges to create nano-scale therapeutics and diagnostics, it is still 
essential to embed targeting capability to these novel systems to make them useful. 
Design of robust nanomedicine with universal targeting capabilities could provide 
effective solutions to the ever increasing demand of curing and preventing major 
diseases. 
Diseases like carcinoma & ischemia are accompanied with hypoxia and acidosis. 
Because of the elevated glycolysis and acidosis in the diseased cells, they show a 
lower pH in the surface of the cells which promotes the appearance of aggressive 
malignant cells with enhanced multidrug resistance. Therefore, the extracellular 
acidity can be used as a hallmark to target and deliver nanotheranostics. Thus coating 
nanoparticles with pH (Low) Insertion Peptides (pHLIPs) increase efficiency of 
targeting acidic diseased tissues. This novel method could be used as a promising 
method to create future nanotheranostics for cancer and other diseases which are 
dominating the present world. 
The main goal of the work presented here is to 
 
 Review the field of advanced targeted nanomedicine and its future trends; 
 Design pHLIP® coated lipid & surfactant based nanovesicles to deliver       
therapeutic and diagnostic agents; 
 Use different drugs and dyes for imaging and therapy ; 
 
 Assess the cytotoxicity, targeting capabilities and the cellular interaction of   
these nanovesicles in in- vitro and in-vivo.
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PREFACE 
This dissertation is written in the ‘Manuscript Format’ using the Thesis/ Dissertation 
template of the University of Rhode Island. There are three manuscripts, each organized 
into a chapter. The tables and figures of each manuscript are listed under the 
corresponding chapter in the list of tables and figures. 
The results of my studies presented here were published in three papers: 
1.          Pereira, Mohan C, Yana K. Reshetnyak, and Oleg A. Andreev. "Advanced 
targeted nanomedicine." Journal of biotechnology 202 (2015): 
2.          Wijesinghe, D., Pereira, Mohan C., Lu, A., Reshetnyak, Y. K., & Andreev, O. 
A. “pH dependent transfer of nano-pores into membrane of cancer cells to induce 
apoptosis.” Scientific reports, 3 (2013): 
3.           Pereira, M.C., Monica, P., Carafa, M., Andreev O.A., Reshetnyak, Y.K. Novel 
pHLIP coated niasomes for diagnostic and therapy, in preparation 
 
Work was presented on the following 3 Meetings/Conferences: 
“Formulation and Delivery of Lipophilic Drugs to Cancer Cells by pHLIP® coated   
Liposomes”, World Medical Nanotechnology Congress & Expo, Dallas, TX (2016) 
“pH dependent transfer of nano-pores into membrane of cancer cells to induce 
apoptosis”,CHI's Biologics Formulation & Delivery Summit, Boston, MA (2014). 
“pH dependent transfer of nano-pores into membrane of cancer cells to induce 
apoptosis”, American Physical Society – New England section, Bridgewater, MA 
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Abstract 
Targeted drug delivery has been the major topic in drug formulation and delivery. As 
nanomedicine emerges to create nano scale therapeutics and diagnostics, it is still 
essential to embed targeting capability to these novel systems to make them useful. Here 
I discuss various targeting approaches for delivery of therapeutic and diagnostic nano 
materials in view of search for more universal methods to target diseased tissues. Many 
diseases are accompanied with hypoxia and acidosis. Coating nanoparticles with pH 
Low Insertion Peptides (pHLIPs) increases efficiency of targeting acidic diseased 
tissues. It has been showing promising results to create future nanotheranostics for 
cancer and other diseases which are dominating in the present world.    
 
Keywords: pHLIP, nanomedicine, passive targeting, active targeting, tissue acidity, 
environmental targeting 
Highlights  
• Nanomaterials are used to target both imaging and therapeutic agents 
• Targeting a tumor environment might better address issue of tumor 
heterogeneity  
• pHLIP senses acidity on the surface of cells 
• pHLIP targets nanomaterials to acidic diseased tissue 
• pHLIP promotes cytoplasmic delivery of nanomaterial’s  payloads 
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1. Introduction 
For a long time people have been working on developing therapeutic agents so that they 
can tune pharmacological and pharmacokinetic properties to treat diseases and get 
desired results. In their continuous quest for food and survival, our ancestors must have 
experienced the effects of natural sources of pharmacologically active chemical 
substances produced by organic and inorganic materials such as plants, fungi, insects, 
animal excreta, reptiles and mineral ores for better or for worse. They must have learnt 
to extract active ingredients from natural resources using crude methods and enhanced 
to use as pain killers or to heal wounds or to treat all types of diseases known to them. 
Ebers papyrus, dated back to ~ 1500 BC provides a detailed description of medical 
treatments used   by ancient Egyptians [1, 2]. In early as 7 century AD, metal, mineral 
and herbal based particles called Bhashma has been used in Ayurvedic medicine in 
Indian sub-continent. Modern analysis showed that these formulations contained 
Fe 2 O 3 , FeS 2 , CuS and SiO 2 and also particle sizes were regulated in the range of 1- 
2 µm [3, 4]. Undoubtedly, these ancient knowledge had laid the foundation for modern 
drug formulation and delivery and made a huge breakthrough in this field as the 
chemical analysis became first available to us in 19th century [5 ].  
While the conventional drugs are still being widely used, the innovation of therapeutic 
nanoparticles has been radically changing the future of drug formulation and delivery 
[6-11]. Nanoparticles are becoming more popular due to their unique tunable 
physicochemical properties.  They have shown promising results in delivery of variety 
of molecules improving the therapeutic index of drugs by enhancing their efficacy 
and/or increasing their tolerability in the body. Nano-carries could also improve the 
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bioavailability of water-insoluble drugs, carry large payloads, protect the therapeutic 
agents from physiological barriers, as well as enable the development of novel classes 
of bioactive macromolecules [12]. 
2. Targeted delivery of nanoparticles 
Almost a century ago, Paul Ehrlich introduced the concept of targeted drug delivery. It 
was considered as a hypothetical ‘magic bullet’ as an entity consisting of two 
components — the first one should recognize and bind the target, while the second 
should provide a therapeutic action in this target. Currently, the concept of ‘magic 
bullet’ includes a coordinated behavior of three components – drug, targeting moiety 
and pharmaceutical carrier [13]. Nanoparticles can be designed to have all three 
properties of the revised version of Ehrlich’s “magic bullet”, and they could be used as 
therapeutics and/or diagnostics. When designing the nano-drugs it is essential to 
understand the target region. Target regions could be whole organs (heart, lung, brain, 
liver and etc), tissues (muscle), cells (nerve, dendrite and etc), disease specific structures 
(tumor cells) or cellular components.  The efficacy of the therapeutics, effectiveness of 
the diagnostics, safety, affordability and access will measure the final success of 
nanoparticles in medicine in regard to its applied value to the patients.   
3. Three major ways of delivery of nanoparticles 
Nanoparticle drug delivery systems use the characteristics of disease tissues to 
selectively target their payloads, either by passive, active or physical targeting [14, 15]. 
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3.1  Passive targeting 
When nanoparticles localize into specific organs or site of disease via biological 
mechanisms, such as RES (reticuloendothelial system) or EPR (enhanced permeability 
and retention) effects, they are known as 'passive targeting agents' [16]. 
RES also called macrophage system or mononuclear phagocyte system, is a class of 
cells which are part of the body’s defense mechanisms. If nanoparticles are not protected 
against RES, they will end up in liver, spleen or lymph nodes very soon. Even though 
this seems to be a disadvantage, RES mechanism can be successfully used  for mapping 
liver [16-21], spleen [18, 19, 22-25] and lymph nodes [17, 18, 22]. The information gain 
from mapping of lymph nodes gives vital indications for cancer staging and metastatic 
potential of tumor, which could prevent unnecessary dissection surgery. 
The EPR effect is very common for most of the solid tumors and has been exploiting as 
a passive mechanism to deliver therapeutic agents. As tumor grows its architecture of 
vasculature become quite abnormal, showing lack of lymphatic drainage and leaky 
blood vessels. This allows the long circulating nanoparticles to accumulate in tumor site 
overtime at higher levels compared to other organs [26-34].  
 
3.2 Active Targeting 
Active targeting uses peripherally conjugated specific targeting moieties for enhanced 
delivery of nanoparticles. The targeting moieties are various ligands including 
antibodies, peptides, aptamers or small molecules that possess high affinity toward 
unique molecular signatures found in diseased tissue to achieve active targeting [35]. 
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Three general categories of active targeting methods are i) angiogenesis-associated 
targeting, ii) uncontrolled cell proliferation targeting and iii) tumor cell targeting.  
Chemical stimulation for angiogenesis is caused by variety of proangiogenic factors 
such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor 
(bFGF). They are the key ingredients of this very complex biological mechanism which 
is essential for life. Pathological angiogenesis or abnormally rapid proliferation of blood 
vessels is common for growth of solid tumors. Therefore the targeting of angiogenesis 
has become a focus for cancer therapeutics [34, 36-42]. Thus, the growth factors are 
attacked by inhibitors of angiogenesis to regulate the tumor progression [43, 44]. 
Another significant target for cancer cells are the cell proliferation markers. These 
markers are not unique to cancer cells but they are overexpressed in certain cancer cells. 
The human epidermal receptors (HER), transferrin receptors and folate receptors are 
widely being employed.  Actively targeting nanoparticles have been using the 
monoclonal antibodies to target overexpressed cell proliferation receptors [35, 45-48].  
According to the American Cancer Society statistics, in US, it is estimated that more 
than 1.6 million new cases of cancer will be diagnosed and more than 0.5 million cancer 
deaths will occur in 2014. The four most common types of cancers that will be 
diagnosed in 2014 in the United States are breast in women and prostate in men, lung, 
and colorectal.  Therefore targeting of specific tumor cells is becoming another popular 
area. FDA has already approved several monoclonal antibodies for the treatment of 
specific types of cancers. Trastuzumab, a humanized monoclonal antibody against 
HER-2 which is overexpressed in human breast cancer, for the treatment of HER-2-
positive metastatic breast cancer was introduced in 1998. Panitumumab, a human 
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antibody against EGFR produced in transgenic mice (XenoMouse), for the treatment of 
EGFR-positive colorectal cancer was approved in 2006. Avastin, a humanized antibody 
against VEGF, for the treatment of metastatic colorectal cancer was introduced in 2004. 
Cetuximab, a chimeric antibody directed to EGFR (HER-1) for the treatment of 
advanced colorectal cancer appeared in 2004. Avastin® (Genentech, South San 
Francisco, CA) is a recombinant humanized anti-VEGF monoclonal antibody for the 
treatment of non-small cell lung cancer, metastatic colorectal cancer and metastatic 
breast cancer were approved [35].  
The major advantage of the active targeting over the passive targeting is a selective 
delivery of nanoparticles to the specific tumors/pathogenic tissues, which remain in the 
site of disease for an extended period of time, thereby increasing the local accumulation 
of the nanoparticles in the sites of interest. [49-52]. However, the heterogeneity and 
adaptability of cancers are difficult to overcome, which makes it problematic to create 
a common cure based on active targeting. Therefore, it is important to identify a 
universal hallmark for majority of cancers or consider use of external physical stimuli 
as a targeting strategy.  
3.3  Physical Targeting 
In many cases, pathological area differs from normal tissues in certain physical 
properties, such as temperature, lack of oxygen and pH. These natural properties are 
common for majority of cancers independent of origin, and could be exploited as 
targeting approaches. The principle behind use of nanoparticles for physical targeting is 
that a stimulus, which may be applied externally or originate within the pathological 
site, induces either a physical change in the structure of the nanoparticle itself, thereby 
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causing the eradication of the target or  modulating the rate at which an embedded drug 
is released. pH, lack of oxygen, temperature, ultrasound, electromagnetic radiation and 
mechanical forces serve as stimuli for physical targeting.  
 
3.3.1 Magnetic-sensitive systems  
Use of magnetic sensitive nanoparticles was first proposed by Widder, Senyi and their 
colleagues in late 1970s  [53, 54]. These nanoparticles are primarily fabricated in such 
way that therapeutic agents are attached to, or encapsulated within, a magnetic core or 
shell by giving capability of functionalizing their surfaces. Once functionalized, the 
nanoparticles are injected into the bloodstream, often using a catheter to position the 
injection site near the target. Powerful rare earth magnets are focused over the target 
site to apply magnetic fields with high-gradient and the forces affecting the particles. 
So, the field permits nanoparticles to be captured and released at the target. Clinical 
trials done by Koda et al. to deliver doxorubicin hydrochloride showed great deal of 
success for hepatocellular carcinoma [55].  This method may be effective for targets 
close to the body’s surface, but as the magnetic field strength falls off rapidly with 
distance, sites deeper within the body become more difficult to target [56]. Several 
groups recently proposed a way to overcome this hurdle by implanting magnets near the 
target site, within the body [57, 58]. However, this method is invasive and not 
systematic, which apply significant restrictions for clinical use. Moreover this method 
would not target metastases, which make cancer a lethal disease.   
Key advantages of magnetic NPs are they can be (i) visualized (super paramagnetic NPs 
are used in MRI);[59, 60] (ii) guided or held in place by means of a magnetic field; (iii) 
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heated in a magnetic field to trigger drug release or to produce  hyperthermia/ablation 
of tissue; (iv) targeted specific locations in the body; (v) reduced the quantity of drug 
needed to attain a particular concentration in the vicinity of the target; (vi) reduced of 
the concentration of the drug at non target sites minimizing severe side effects and (vii) 
used to perform magnetic guided surgeries for surgically impossible tumors either due 
to too hemorrhagic or localized in tissues with high risk of healthy tissue injury.  
Despite of these advantages they also inherit limitations. MNPs accumulate throughout 
the cross section from the external source to the depth marking the effective field limit 
which is a drawback. Magnetic agglomeration at the absence of magnetic field is tackled 
by superparamagnetic NPs. Creation of smaller NPs, is essential to achieve super-
paramagnetism. As the size becomes smaller, particles’ response to the magnetic field 
is remarkably reduced. As a result of that it makes difficult to direct particles and keep 
them in the proximity of the target while withstanding the drag of blood flow.  
3.3.2 Ultrasound-sensitive systems  
When nanoparticles are used to target solid tumors, homogeneous distribution of most 
of them in tumor is always questionable. Although nanoparticles can extravasate from 
the blood to the extracellular matrix, they do not always travel far away from the blood 
vessels. Thus, only a small population of cancer cells located close to the blood vessels 
will be exposed to the cytotoxic drugs thus minimizing it’s therapeutic index. As 
nanoparticles stay for longer periods of time, they could target and bring harm to normal 
tissues. Researchers have explored ways to use ultrasound to enhance the cellular uptake 
of nanoparticles in the target sites by increasing the permeability of the capillary walls, 
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pushing them through the extracellular matrix, enhancing the release of the drug from 
the nanoparticles and improving the cellular uptake.  
Escoffre  and his colleagues showed on 2D and 3D in vitro models that the focused-
ultrasound  not only helps nanoparticles to penetrate into the interior of the tumor, it 
also helps to release drugs to the intercellular space without altering chemical properties 
[61-64]. The use of phenomenon of cavitation, which is the formation of bubbles in a 
medium exposed to intense focused ultrasound to disrupt the targeted tissue, is another 
application of this kind. Microbubble-based drug-delivery vehicles can flow through the 
vasculature into the ultrasound focal zone within the tumor region and they can release 
payloads upon the rupture. These bubbles can be also used as imaging contrast agents 
to improve diagnosis and detection of cancer [65-69].   
Non-invasiveness, the absence of ionizing radiations, and the facile regulation of tissue 
penetration depth by tuning frequency, duty cycles and time of exposure can be 
identified as the main advantages of using ultrasound sensitive systems [70].  
Ultrasound can trigger release of drugs from various nanocarriers by destabilization. 
Ultrasound triggered delivery systems has the ability to release drugs into cytosol as 
result of pore formation in the cell membrane. Therefore they can bypass degenerative 
endocytotic pathway which is especially useful in DNA transfection [71]. Low 
frequency ultrasounds can be used to promote the delivery of some liposomal based 
drugs through the skin to inhibit progression of melanocytic lesions[72]. However, the 
increased vessel permeability through ultrasound can also impact negatively by 
promoting metastatic dissemination. Possible metastatic dissemination can be 
minimized by using NPs containing agents, which are able to efficiently interact with 
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ultrasonic waves and decrease the threshold frequencies of ultrasound waves. 
Effectiveness of microbubbles based drug delivery for tissue targeting may be limited 
by their short lifespan and absence of extravasation. The development of 
perfluorocarbon (PFC) nanoemulsions  and PFC droplets functionalized with aptamers, 
which can be converted into microbubbles under therapeutic ultrasounds have 
significantly improved cellular uptake and/or release of drugs in tumor sites[73].     
3.3.3 Temperature-sensitive systems 
Above we gave examples of external stimuli applied to diseased area to enhance 
delivery of nanoparticles and/or release of imaging/therapeutic moieties. Another 
approach relays on exploration of natural properties or microenvironment in diseased 
tissue. It is observed that certain types of malignant cancer (bladder, prostate and etc) 
[74] and some other disease conditions show difference in local temperature compared 
to normal tissues. Understanding of the differences of local temperature in pathological 
sites paved the path to temperature-sensitive delivery systems. Long circulating, 
thermo-sensitive nanocarriers can be fabricated and used to exploit micro-
environmental temperature differences in diseased sites. For example, in 1978, 
Yatvin et al. first time suggested a method to use temperature-sensitive liposomes to 
target mild hyperthermia in disease sites. Active or passive targeting methods have to 
be first employed to accumulate thermo-sensitive nanocarriers in targeted sites. As the 
nanocarriers accumulate in target sites, carried drugs are released in response to the 
micro-environmental temperature in more controlled manner.  
In general, the thermo-sensitive polymers have the ability to swell and de-swell, 
depending on temperature. The two basic types of thermo-sensitive materials are: i) 
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positive temperature-sensitive hydrogels that are swollen and hydrated at higher 
temperatures and contract on cooling below the upper critical solution temperature 
(UCST) and ii) negative temperature-sensitive hydrogels that are swollen at lower 
temperatures and contract on heating above the lower critical solution temperature 
(LCST). Water solubility of the system decreases as temperature increases. The latest 
type of system dominates the literature on drug release applications [75]. Upon the 
introduction of UCST/LCST polymers to nanocarrier systems, they gained the ability to 
actively respond to the temperature changes in the microenvironment. As they respond 
to the environmental temperature these systems remarkably change their features such 
as conformation, solubility and hydrophilic/hydrophobic balance to release therapeutic 
agents in those sites [76]. 
Injectable thermo-sensitive hydrogel systems are also considered as potential thermo-
sensitive nano-carries owe to their number of advantages, including simplicity of drug 
formulation, protective environment for drugs, prolonged and localized drug delivery, 
and ease of application. Chitosan and related derivatives, poly(N-isopropylacrylamide)-
based (PNIPAAM) copolymers, poly(ethylene oxide)/poly(propylene oxide) 
(PEO/PPO) copolymers and its derivatives, and poly(ethylene glycol)/ biodegradable 
polyester copolymers are widely used by researchers to construct injectable thermo-
sensitive hydrogels [74, 77-80].  
DPPC/DSPC are the most common lipids used in making thermo sensitive liposomes. 
With the right lipid composition temperature- dependent fusion of liposomes can be 
achieved at mild hyperthermia region (39 °C- 42 °C) enhancing increased level of drug 
available at the diseased site  [75]. Early in vivo work done over a range of tumor 
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models, including various carcinomas, sarcomas, and lymph node metastases, and over 
a range of drugs, including adriamycin, methotrexate, bleomycin and cisplatin  showed 
the benefits of temperature-sensitive liposomes when use with mild hyperthermia [81-
87]. Temperature sensitive nano-systems offer numerous advantages such as 
elimination of invasive surgical procedures, the ability to bypass physiological barriers, 
and allowing drugs to reach hard-to-access sites in the body, ability to stealth the thermo 
sensitive systems against immune system and environmental degradation and ability to 
combine this with induced hyperthermia. Owe to extensive studies done in these 
systems over past three decades that gives the capability for wide variety of choices to 
design nanocarriers of desired architectures.  Limitations of thermo-sensitive 
nanocarriers can be overcome by combining them with additional stimuli-responsive 
materials.  
3.3.4 Targeting hypoxia 
Hypoxia (low oxygen concentrations) plays a vital role in many tumors by contributing 
to chemoresistance, radioresistance, angiogenesis, vasculogenesis, invasiveness, 
resistance to cell death, altered metabolism and genomic instability. The hypoxic 
regions often lie surrounding areas of necrosis in solid tumors [88-90]. Hypoxia-
inducible factor (HIF), which is a transcriptional complex, acts as the hypoxia sensor in 
a cell. Overexpression of HIF-α, the regulatory subunit of HIF is a measure of increased 
vascular density, severity of tumor grade, failure of conventional treatment and 
prognosis. Therefore HIF has become an attractive, direct and indirect therapeutic target 
in recent years [91-93]. Thambi et al. reported about self-assembled nanoparticles called 
hypoxia-responsive nanoparticles, which can selectively release hydrophobic agents 
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under hypoxic conditions [94].  In vivo studies showed selective accumulation of 
nanoparticles at the hypoxic regions in tumors compared to normal cells. 
Development of hypoxia targeting nanoparticles opens new paths to overcome drug 
delivery impediments mentioned earlier. For instance, the brain which demands high 
amount of oxygen is vulnerable to hypoxia as a result of irregularity of the blood flow 
induced by either cardiac failure, traumatic brain injury, brain cancer or subcortical 
vascular disease. Neuronal dysfunction and cell death in major neurodegenerative 
diseases also have direct and indirect links to hypoxia. Since HIF involved in virtually 
all aspects of the response to hypoxia, HIF based nanocarriers have the potential 
advantage of simultaneously regulating the expression of a large number of genes thus 
treatment of diseases. However, for HIF related therapies it is vital to discriminate 
between various HIF isoforms [95, 96]. Another potential advantage of hypoxia 
targeting NPs is the ability to treat inaccessible brain tumors, which cannot be achieved 
through conventional surgeries.  
3.3.5 Targeting acidity 
It’s well known that the cancer cells undergo glycolysis even in the presence of oxygen 
which has very significant importance to cancer cells survival and proliferation.  As a 
result, high glycolytic activity and production of carbonic and lactic acids, which are 
intensively pumped out cells to keep intracellular pH near neutral, are common 
characteristics of solid tumors. It leads to extracellular acidification of tumor 
microenvironment, which promotes cancer invasiveness and aggressiveness [97-100]. 
This acidic microenvironment is common even for several other diseased tissues, such 
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as ischemia, inflammation, arthritis and atherosclerosis. Thus, extracellular acidity 
might serve as a general marker for detecting and targeting of diseased tissue.  
pH-sensitive nanoparticle systems are the one of the well-studied delivery systems. 
These systems contain pH sensitive polymers, lipids or peptides such as pHLIPs (pH 
Low Insertion Peptides). Key principle of making pH sensitive fusogenic liposomes is 
to identify a lipid which is stable at physiological pH but destabilized upon acidification 
following cellular internalization, thereby, promoting the release of their contents into 
the cytosol. First generation of such liposomes are designed using the cone shape of 
phosphatidylethanolamine (PE) lipids [101]. Cytoplasmic delivery of membrane-
impermeable therapeutic agents has been improved by the DOPE-based pH sensitive 
liposomes [102-104]. The layer-by-layer (LbL) nanoparticle assembling technique is 
developed to prepare pH-sensitive nanoparticles. They contain a pH-sensitive outer 
stealth layer which allows targeting and retaining of nanoparticles in acidic tumor 
regions [105]. 
 pH sensitive systems can be also achieved by the self-assembled surfactants. They are 
mostly known as niosomes and analogues to liposomes. For example, Di Marzio and 
colleagues reported that the use of non-ionic surfactants polysorbate 20 and polysorbate 
21 together with cholesterol can form highly stable pH sensitive nano-vesicles which 
have the potential to deliver both hydrophilic and hydrophobic therapeutic agents to 
target sites [106]. pH sensitive systems also show great success for delivering drugs 
through oral drug administration due to vast environmental pH differences in 
gastrointestinal system [107-109]. The development of highly pH sensitive NPs to target 
 
 
17 
 
acidity helps not only for treatments but also for diagnosis of wide array of carcinomas 
and many other pathological diseases.   
4. pHLIP-technology 
The pHLIP technology, which was introduced several years ago, has been showing 
success in targeted drug delivery for cancer and other pathogenic conditions. pHLIP, 
being a membrane peptide, has affinity to cellular membranes and it targets extracellular 
acidity. In contrast to other pH-sensitive systems, it “senses” acidity at the surface of 
cancer cells, where pH is the lowest due to the reversed pH gradient compared to cells 
in healthy tissue [110]. 
4.1. Molecular mechanism of pHLIP action 
The original pHLIP composed of 36 amino acids is an isolated C-helix of 
bacteriorhodopsin.  The water-soluble pHLIP peptide has been observed to behave 
differently at different pHs when it is in the vicinity of the lipid bilayer. The pHLIP  
binds to lipid bilayer surfaces as an unstructured monomer above pH 7, and it 
spontaneously inserts as an α-helix across lipid bilayers at  low pH, with a pKapp of 6 
[111]. The insertion of pHLIP into membrane, is reversible and unidirectional, in most 
cases the C-terminus is translocated across the membrane whereas the N-terminus stays 
outside of the membrane [112, 113]. The opposite occurs for reverse sequence [114].  
The insertion mechanism is based on the protonation of Asp/Glu residues located in the 
membrane inserting parts of the pHLIP [111, 115-117]. The thermodynamics and 
kinetics of pHLIPs membrane-associated folding and insertion has been extensively 
investigated. Peptide’s three major forms (in solution, attached to, and inserted across 
lipid bilayers ) are monomeric at peptide concentration less than ~ 7 µM [112]. The 
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process of insertion and folding (helix formation) is fast and varies from milliseconds 
to minute depending on peptide sequence (Andreev et al., 2010; Karabadzhak et al., 
2012). The energy of peptide’s association with bilayer is about 6-7 kcal/mol [113]. As 
pHLIP inserts into the membrane and folds it releases additional energy (about 2 
kcal/mol) [113], which could be utilized to tether cargo molecules to the surface of 
cancer cells (Fig 1a), or move cell impermeable cargo molecules across the membrane 
into a cell (Fig. 1b). It has been shown tumor targeting of fluorescent, PET and SPECT 
probes attached to the N-terminus of pHLIP [118-123].  As biological membrane 
remains the main barrier for cytoplasmic drug delivery it was demonstrated that the 
energy of membrane-associated folding of pHLIP can be used to successfully deliver 
into cells polar and membrane-impermeable molecules including cyclic peptides, 
toxins, peptide nucleic acids (PNAs) linked to pHLIP’s C-terminus via cleavable links 
[124-128]. Over a decade the original pHLIP peptide has given birth to more than 20 
pHLIP variants and available to use as probing and delivery agent [114].  The ability of 
pHLIP to probe extracellular acidic environment, which is associated with tumors and 
many other pathological conditions has opened new avenues for future drug delivery.   
 
4.2. pHLIP based nanomedicine 
Roughly a half a century ago, a British biophysicist and a medical scientist, Alec 
Bangham made a remarkable observation that phospholipids in aqueous systems can 
form closed bilayered structures and named them Bangasomes. Today we call them 
liposomes. After Bangham and his collaborators established the existence of liposomes, 
the liposomes have moved a long journey from being just another exotic entity of 
biophysical and colloidal science research and became a pharmaceutical carrier of 
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choice for various real-world applications, as we outlines in previous sections. As a 
result of that, now liposomal drugs has approved for clinical applications or they are 
undergoing clinical evaluation [129].  
When pHLIP is introduced to the conventional liposomes as a coating moiety (Fig. 1c), 
it allows to enhance the therapeutic value of the liposomes. It was shown that the 
presence of pHLIP on the surface of PEGylated-liposomes enhanced membrane fusion 
and lipid exchange in a pH dependent fashion, leading to increase of cellular uptake and 
payload release (Fig. 1d), and inhibition of cell proliferation by liposomes containing 
ceramide [130]. For liposomal drug production and storage the controlling of their size 
becomes a major issue. When liposomes are in storage they could fuse with each other 
and give a poly-disperse liposomal mixture and diminish the desirable properties as 
nano-carriers.   The same study [131] reveals that liposomes containing just 5% of 
pHLIP lipid composition minimize inter-liposomal fusion and make them stable for 
several days if stored at neutral pH, since pHLIP brings overall negative charge to the 
surface of liposomes at neutral and high pHs. At the same time, drop of a pH leads to 
the protonation of Asp/Glu residues, reduces overall negative charge at the surface of 
liposomes and enhances interaction of pHLIP-coated liposomes with cellular 
membranes. It was studied the interaction between pHLIP-coated liposomes and cells 
as a function of incubation time of 15 min vs. 60 min and it was shown existence of 
different pathways of liposome-cell interaction. Predominantly direct liposomal fusion 
with plasma membrane occurs during short incubation period; while during long 
incubation period, both fusion and cellular internalization through endocytosis (most 
probably, macro pinocytosis) could happen. Since pegylation helps to prevent 
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opsonization, it promotes longer circulation of liposomes in blood, and enhances 
probability for liposomes to interact with cell membrane in a pH dependent manner.  
Thus, the pH-sensitive, "fusogenic" pHLIP-coated liposomes could be used to 
selectively deliver various diagnostic and therapeutic agents to acidic diseased cells.  
Emmetiere et al. [132] (Emmetiere et al., 2013) introduced dual-delivery approach using 
pHLIP to tether liposomes to cancer cells in tumor [132]. First, pHLIP was conjugated 
to the tetrazine (Tz), which is one of the bioorthogonally reactive small molecules to 
form pHLIP-Tz conjugate. pHLIP-Tz was injected into mice to selectively label the 
surface of cancer cells. Then, bioorthogonally reactive trans-cyclooctenes coated 
liposomes containing 18F PET isotope were given as a second injection. The long 
circulating radiolabeled liposomes were accumulated in tumor sites mainly via EPR 
effect, followed the click reaction between tetrazine-pHLIP and trans-cyclooctenes in 
liposome coat resulting in covalent conjugation and tethering of liposomes to cancer 
cells. This in vivo click reaction allows achieving high signal/noise ratio, higher 
accumulation of radiolabeled liposomes in tumor site, low nonspeciﬁc binding and 
reduced toxicity to kidneys and bone marrow. 
According to the World Health Organization statistics the ischemic heart diseases are 
the top leading cause of death, affecting millions of men and women worldwide. Several 
techniques for passive and active imaging and as well as drug delivery to the  diseased 
cardiac tissue have been developed during past few years [133, 134], which including 
different types of nanoparticles for drug delivery such as liposomes, drug–polymer 
conjugates, polymeric micelles, dendrimers, nanoshells, and nucleic acid-based carriers 
[129, 135, 136]. A study was done to evaluate ability of pHLIP-coated liposomes to 
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target ischemic myocardium  using two murine ischemia models: regional ischemia 
induced by coronary artery occlusion and global low-flow ischemia in isolated hearts 
[137].  In both models, two candidates from the pHLIP family (WT and Var7) were 
chosen along with pH insensitive kVar7 (K-pHLIP), which has Lys instead of key 
Asp/Glu residues and cannot insert into membrane at any pH [114]. It was shown that 
pHLIP-coated liposomes bind to ischemic regions but not to normal myocardium while 
kVar7 and liposomes coated just with PEG  (no pHLIP) do not  show any targeting 
[137]. The study ensures that pHLIP-coated liposomes have the ability to target 
ischemic regions with therapeutic agents as well as to mark disease regions to assist 
pHLIP-fluorescent-aided cardiac surgeries.    
Another novel approach of pHLIP-coated-liposomes is the delivery of nano-pores to 
induce apoptosis in cancer cells [138]. Proper ion balance between intracellular and 
extracellular media is crucial for normal cell functioning. Any alterations in the 
conductance of membranes for ions will lead to cell death. To change cellular ion 
ballance the pore-forming gramicidin A (10 mol%) was delivered to cellular membrane 
using pHLIP-coated DOPC liposomes. Liposomes were stable for more than a month 
in 4 °C. Hydrophobic gramicidin A monomers were introduced into pHLIP-coated-
liposomes, where it makes beta-helices and forms transmembrane porse with diameter 
of 4-5 Å that can transfer monovalent cations through the membrane at rate of 107 
cations per second [139]. As we outlined above, when pHLIP-coated liposomes target 
cancer cells, they either fuse with the plasma membrane or are up-taken by endocytosis 
and then fuse with lysosomal membranes. It leads to delivery of gramicidin A pores 
(nano-pores) to cellular membranes of cancer cells. These nano-pores acidify the 
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intracellular space and eliminate the vital Na+/K+ ion balance. This method not only 
opens pathways to treat acidic solid tumors, but also give opportunity to deliver various 
membrane peptides and proteins to the cells, widening the applications in biotechnology 
and nano-medicine.  
Nano-gold particles have also caught attention in pHLIP-nanotechnology.  Beneficial 
properties of gold in medicine has been considered for centuries [140]. And gold has 
been used in modern science as a contrast agent in electron microscopy.  There are well-
established methods to obtain uniform stable gold nano-structures in the range of few 
nanometers up to couple hundred of nanometers [141]. Tuning size and shape of nano-
gold structures allows to obtain unique physical properties, which can be very useful for 
multiple applications across both therapeutics and diagnostics [142].  Functionalized 
nano-gold particles are valuable for wide variety of nanomedicinal uses and now they 
are undergoing through evaluations  of toxicity [141], stability [143], pharmacokinetics 
[144], cellular trafficking [145-148], efficacy for gene regulation [149] and drug 
delivery [147], and use in photo-thermal therapies  [150, 151]. 
Lan et al. showed that nano-gold particles which are 1.4 nm size in diameter conjugated 
to N-terminus of pHLIP can successfully target cancer cells at low pH [131]. In vivo 
studies done using mice-tumor models demonstrated high tumor uptake in both 
intravenous and intra-tumoral administration compared to non-functionalized nano-
gold particles. The beauty of pHLIP-nano gold technology is in its capability of 
providing the specific targeting, enhancing local concentration in tumor mass in 
homogeneous way while remaining in cells for an extended period (several days), by 
allowing applications of radiation therapy and imaging.  
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Davies and colleagues employed pHLIP to deliver luminescent europium coated 
nanoparticles into platelets [152]. The 13 nm gold nanoparticles were co-coated with a 
europium luminescent, EuL and the pHLIP to give pHLIP.EuL.Au. Human platelets are 
vulnerable to transfection or microinjection. But with this method authors could deliver 
nanoparticles which have roughly 640 lanthanide probes per particle. The result shows 
that the internalization of nanoparticles into the platelets happened only at low pH and 
not at normal pH. The significance of this research is that pHLIP can translocate 
multimodal nanoparticles in a pH dependent manner.  
Non-viral vectors are also a hot topic in gene therapy due to their advantages over viral 
vectors such as simplicity of use, ease of large-scale production and lack of specific 
immune response  [153]. Recently it was reported a novel use of pHLIP to deliver pDNA 
to tumor cells [154]. DGL-PEG-pHLIP were made by conjugating the surface of 
dendrigraft poly-L-lysines (DGLs, generation 3 with 123 amino groups per molecule) 
to the N-terminus of pHLIP followed by electrostatic interactions between negatively 
charged pDNA and positively charged DGL head group of DGL-PEG-pHLIP to create 
DGL-PEG-pHLIP/pDNA nanoparticles. Results of in vitro studies showed that higher 
cellular uptake of nanoparticles occurs at low pH (pH 6.0) compared to normal pH (pH 
7.4) and nanoparticles enter cells mainly by adsorptive mediated endocytosis. The in 
vivo studies also followed the same pattern by showing high tumor uptake of DGL-
PEG-pHLIP/pDNA nanoparticles. It was clear that pHLIP enhanced the pH-controlled 
localization of the nanoparticles in tumors.  
Zhao and colleagues (2013) show that pHLIP peptide not only targets acidic tumor 
micro environment but also it can release nanoparticles in a controlled manner to the 
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intracellular space. They chose mesoporous silica nanoparticles (MSN), in particular 
MCN-41, to load with doxorubicin. MSN has the attributes of high homogeneous 
porosity, inertness, biocompatibility, high payload capacity and easy surface 
functionalization capability. The MSN particles were attached to the C-terminus of 
pHLIP by disulfide bond. At low pH (< 6.5), doxorubicin-loaded pHLIPss-MSN rapidly 
inserted into the cell membrane and translocated MSN into cytoplasm.  The disulfide 
bond was cleaved in cytoplasm to release doxorubicin. 
 
5. Conclusion 
There are several challenges for targeted nano drug delivery systems to overcome. Still 
most of these drug systems undergo in vitro and in vivo testing using animal models. 
Therefore their relevancy to the real patients has to be evaluated extensively. Each nano 
drug platform is distinctive and need to be assessed experimentally as new system, 
which is strenuous. Nanoparticles stability, size uniformity, controlled drug release rate, 
sterile preparations in large scale and manufacturing cost have to be addressed in order 
to make them available to the market.  But with recent scientific advances, next ten 
years it is expected to see large number of targeted drug delivery systems based on 
nanoparticles in the market. pHLIP nanotechnology has been showing its potential 
capability to address most of the challenges mentioned above. pHLIP technology used 
alone or combined with other approaches might lead to new formulations translatable 
to clinics.   
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Tables 
 
Table 1. Current pHLIP applications in nanotechnology  
 
 
 
 
 
 
 
pHLIP 
nanotechnology 
How it works Administration Authors 
PEGylated-liposomes 
containing ceramide 
Increase ceramide levels in 
cancer tissues promote cell 
death and tumor inhibition 
In-vitro , In-vivo [155] 
pHLIP-Tz conjugates  
and trans-cyclooctenes 
coated liposomes 
containing 18F PET 
isotopes  
Tetrazine(Tz) labeled cancer 
cells are targeted by trans-
cyclooctenes coated 
liposomes to radio label the 
tumor site   
In-vivo [132] 
WT and Var7 coated 
liposomes  
pHLIP coated liposomes 
binds to ischemic regions and 
assist pHLIP- fluorescent -
aided cardiac surgeries 
In-vivo [137] 
pHLIP liposomal 
nano-pores  
Hydrophobic gA is delivered 
to cancer cells to form 
channels in cell membrane to 
destroy ion balance and 
induce apoptosis 
In-vitro [138] 
pHLIP  nano-gold 
particles  
Homogeneous accumulation 
of gold in tumor sites allow 
radiation therapy and imaging 
In-vivo [131] 
Eu coated pHLIP 
nanoparticles  
At low pH, more lanthanide  
probes can be internalized to 
human platelets breaking the 
targeting barrier   
In-vitro [152] 
pDNA nanoparticles High uptake of DGL-PEG-
pHLIP/pDNA in tumors 
In-vivo, In-vitro [156] 
dox MSNs Dox are loaded to porous 
silica nanoparticles and 
deliver to cancer cells using 
pHLIP 
In-vitro [157] 
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Figures 
 
Figure1. Different applications of pHLIP for targeting of acidic tissues. Tethering 
of cargo molecules to the surface of cells (a). Cytoplasmic delivery of cargo molecules 
and it’s release by break of cleavable link (shown in blue) (b). Assembly of 
multifunctional pHLIP-coated liposomes containing polar (green) and hydrophobic 
(yellow) payloads (c). Schematic presentation of interactions of lipid bilayer of the 
pHLIP-coated multifunctional liposomes with plasma membrane of a cell (presentation 
of liposome in the endosome is schematic and not in a scale) (d). 
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Abstract 
Proper balance of ions in intracellular and extracellular space is the key for normal cell 
functioning. Changes in the conductance of membranes for ions will lead to cell death. 
One of the main differences between normal and cancerous cells is the low extracellular 
pHe and the reverse pH gradient: intracellular pHi is higher than extracellular pHe. We 
report here pH-selective transfer of nano-pores to cancer cells for the dis-regulation of 
balance of monovalent cations to induce cell death at mildly acidic pHe as it is in most 
solid tumors. Our approach is based on the pH-sensitive fusion of cellular membrane 
with the liposomes containing gramicidin A forming cation-conductive 𝛽-helix in the 
membrane. Fusion is promoted only at low extracellular pH by the pH (Low) Insertion 
Peptide (pHLIP®) attached to the liposomes. Gramicidin channels inserted into the 
cancer cells open flux of protons into the cytoplasm and disrupt balance of other 
monovalent cations, which induces cell  apoptosis. 
Introduction  
The control of intracellular pH and balance of ions in a cell are essential for a 
number of important physio- logical processes, such as protein, DNA and RNA 
synthesis and control of the cell cycle[1]. In cancerous tissue the balance of 
protons is disturbed, which leads to acidification of the extracellular milieu and 
reversing of the transmembrane pH gradient compared with normal tissue: the 
intracellular pH (pHi) in tumors is higher than the extracellular pH (pHe)[2, 3]. 
The equilibration of the extracellular and intracellular pHs as well as disruption 
of balance of other ions will lead to cell death. We propose to transfer in a pH-
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dependent manner nano-pores to the plasma membrane of cancer cells to disrupt 
intracellular and extracellular ion balance and induce cytosol acidification. 
Nano-pores will be formed by linear hydrophobic peptide, gramicidin A (gA), 
consisting of alternating L- and D-amino acids, which forms cation-conductive 𝛽-
helix in the membrane[4-6]. The diameter of gA 𝛽- helix channel is about 4–5 Å , 
which can conduct about 107 cations per second[5]. The high conductance is 
observed 
for the protons, sodium and potassium ions. The gA channels formed in the 
liposomes will be delivered to the membrane of cancer cells by fusion. The 
fusion between the lipid bilayer of liposome and cancer cells will be promoted 
by the pH (Low) Insertion Peptide (pHLIP®). The pHLIP inserts into the lipid 
bilayer and forms transmembrane helix at pH < 7 [7, 8], and therefore is able to 
bring in close contact liposome and cellular membranes only at low pH. We have 
demonstrated that the pHLIP-based optical, PET and SPECT imaging agents can 
target acidic diseased tissue[9-13], and we proved that pHLIP technology can 
substantially improve delivery of nanopar ticles and liposomes to the acidic 
diseased tissue[14, 15]. The presence of pHLIP on the surface of PEGylated- 
liposomes enhanced membrane fusion and lipid exchange in a pH dependent 
fashion, leading to the increase of cellular uptake and payload release[16]. In the 
present study we demonstrate that the pHLIP-coated liposomes could be used to 
transfer nano-pores (peptide channels) into the membrane of cancer cells, 
disrupt transmembrane pH gradient and balance of sodium ions, which leads to 
the apoptosis of cancer cells. 
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Materials and Methods 
Materials 
Gramicidin A (gA) (from Bacillus brevis) ≥ 90%(HPLC), N-(fluorescein-5-
thiocarbamoyl)-1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine, 
triethylammonium salt (FITC-DHPE) were purchased from Sigma-Aldrich. 1,2- 
dioleoyl-sn-glycero-3-phosphocholine (DOPC),1,2-dioleoyl-sn-glycero-3- 
phosphoethanolamine-N-[4-(p-maleimidophenyl)butyramide] (sodium salt) 
(DSPE-maleimide), were obtained from Avanti Polar Lipids. The pHLIP peptide 
(ACEQNPIYWARYADWLFTTPLLLLDLALLVDADEGT) was prepared by 
solid- phase peptide synthesis at the W.M. Keck Foundation Biotechnology 
Resource Laboratory at Yale University. 3,3’-dimethyl-a-naphthoxacarbocyanine 
iodide (JC-9), nigericin, SNARF (seminaphthorhodafluors)-5F 5-(and-6)-
carboxylic acid, acetoxymethyl ester, acetate and CoroNaTM Green, AM were 
purchased from Invitrogen. Water was purified using a Millipore Milli-Q system. 
Synthesis of DSPE-pHLIP 
DSPE-pHLIP was synthesized by conjugation of DSPE- maleimide with single cysteine 
residue at the N-terminus of pHLIP. In a typical coupling reaction, 1200 nmol of peptide 
was mixed with 1000 nmol of DSPE- maleimide in 400 µL of degassed methanol and 
incubated overnight stirring at room temperature under  argon. 
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Liposome preparation  
Liposomes were prepared by extrusion: a chloroform solution of the 80–98 mol% of 
DOPC lipids mixed with 5% pHLIP conjugated lipids (pHLIP-DSPE), 2–5% 
fluorescent labeled lipids (FITC-DHPE) and 0–10% gA were evaporated using rotary 
evaporator producing an even thin film, followed by the additional overnight 
evaporation under the high vacuum to remove traces of organic solvents. This lipid 
layer was re-suspended in 1 mL 10 mM phosphate, 150 mM NaCl buffer and went 
through 10 freeze-thaw-vortex cycles. The resulting liposome solution was extruded 
31 times through 50 or 100 nm filters, which were used for biophysical 
measurements and experiments on cultured cells, respectively. 
Liposomes were sterilized by filtering through 0.2 µm filter before addition to 
cells. Solution of liposomes was kept at 4℃ overnight before use to ensure gA 
channels formation. The concentration of lipids was calculated by measuring 
absorbance of FITC at 496 nm (ε= 89,000 M
-1 cm-1) or gA and pHLIP at 280 
nm (ε =21,000 M
-1 cm
-1 for gA and ε= 13,940 M
-1 cm
-1 for pHLIP) of the 
liposomes dissolved in methanol. 
DLS and Zeta potential measurements 
The size of liposomes was measured by the dynamic light scattering (DLS) using a 
Malvern Zetasizer Nano ZS instrument with Malvern disposable cuvettes (Malvern 
USA). Samples were typically 100 nmol liposomes in 1 mL of 10 mM phosphate, 
150 mM NaCl, pH 7.4 buffer. The zeta potential was measured on the same 
instrument using folded capillary cells from Malvern. 
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Cryo-electron microscopy 
 About 5 µL droplet of liposome solution was spread on a Lacey Formar/Carbon 
electron microscopy grid and preserved in a frozen-hydrated state by a rapid 
freezing in liquid ethane. The vitrification process was performed via FEI Vitrobot 
system with the setting of a single blot of 3 sec, an offset of 1, and drain and wait 
time of 1 sec. Samples were imaged using JEOL 2100 TEM with an accelerating 
voltage of 200 kV at magnifications of 20,000× and 40,000×. 
Steady-state fluorescence and circular dichroism measurements 
Tryptophan fluorescence and circular dichroism (CD) measurements were carried 
out on a PC1 ISS spectrofluorometer (ISS, Inc.) and a MOS-450 spectrometer (Bio-
Logic Inc.), respectively. All measurements were performed at 25℃. DOPC 
liposomes containing 0, 2% or 10% of gA were used in the study in phosphate buffer, 
pH 7.4. Fluorescence spectra of gA at excitation of 280 nm was recorded from 310 
nm to 400 nm with the spectral widths of excitation and emission slits set at 4 and 
2 nm, respectively. CD spectra were recorded from 200 to 260 nm with 0.5 nm 
increment using a cuvette with an optical path length of 0.5 cm. 
Kinetics of FITC quenching 
 DOPC liposomes containing 2% and 10% gA, 2% FITC-DHPE and liposomes 
containing no gA were used in the kinetics studies. All solutions were degassed 
several minutes under a vacuum to minimize air bubbles before loading into 
syringes of the stopped-flow apparatus (Bio-Logic, Inc.). Liposomes of 1.5 mM 
lipid concentration in 10 mM phosphate buffer pH 8 (or pH 3) with 150 mM NaCl 
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were rapidly mixed (within 5 ms – dead time of the set up we used) with an equal 
volume of HCl (or NaOH) to have final pH of 3 (or pH 8). Changes of the 
fluorescence intensity of FITC at 519 nm excited at 496 nm were monitored in a 
real time. Baseline was measured by mixing the liposomes with equal volume of the 
buffer. 
Cell lines 
 A549 (lung carcinoma), HeLa (human cervix adenocarcinoma) and M4A4 (human 
breast ductal carcinoma) cell lines were obtained from American Tissue Culture 
Collection (ATCC). Cells were authenticated, stored according to the supplier’s 
instructions, and used within 3 months after frozen aliquot resuscitations. Cells were 
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% 
fetal bovine serum (FBS), 1% penicillin/streptomysin, 1 µg/mL of ciprofloxacin in a 
humidified atmosphere of 5% CO2 and 95% air at 37 ℃. By serial passages some cells 
were adapted for the growth in low pH media (pH 6.2). The pH media was prepared 
by mixing 13.5 g of dry DMEM powder with 0.1 g of sodium bicarbonate in 1 L of 
deionized water supplemented with 10% fetal bovine serum, 1% 
penicillin/streptomysin, 1 µg/mL of ciprofloxacin. 
Proliferation assay 
 About 3,000–4,000 of A549 cells were seeded in 96 well-plates at pH 7.4 and 6.2. 
After 24 hrs, cells were treated for 3 hrs with various concentrations of pHLIP-
coated DOPC liposomes in DMEM at pH 7.4 and 6.0 followed by addition of an 
equal volume of DMEM with 20% FBS. In other experiments, cells were treated with 
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liposomes for 18 hrs followed by the removal of the constructs and replacement of 
the media with DMEM containing 10% FBS. For the control experiments cells were 
treated at both normal and low pHs with the DOPC liposomes containing no gA or 
no pHLIP. Cells were grown until non-treated cells in control reached 80–90% 
confluence. Cell viability was assessed by the colorimetric reagent (CellTiter 96 
AQueous One Solution Assay, Promega) of the MTS (3-(4,5-dimethylthiazol-2-yl)-
5- (3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay, which was 
added for 1 hour to cells followed by measuring absorbance at 490 nm. All samples 
were prepared in triplicate. Each experiment was repeated several times. 
ECIS assay 
Kinetics of inhibition of proliferation of A549 cells treated with the pHLIP-
coated DOPC liposomes containing 10% gA and 5% pHLIP at pH 6.0 were 
monitored by the changes of capacitance measured at AC frequencies on a ECIS® 
8Z (electric cell-substrate impedance sensing) instrument (Applied Biophysics, 
Inc.). Cells (25,000 cells per well) were loaded in 8W10E+ 8-well plate (Applied 
Biophysics, Inc.) and incubated overnight. Next day, the cells were treated with 
different concentrations of liposomes in serum free pH 6.0 media for 3 hrs 
followed by addition of an equal volume of DMEM containing 20% FBS at pH 
6.2. Each well had two sets of 20 circular 250 µm diameter active gold electrodes. 
The changes of capacitance were monitored within 5 days after seeding of cells. 
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Intracellular pH measurements 
 First, pH calibration curve was established: about 40,000 A549 cells were seeded in 
collagen coated glass bottom dishes (MatTek, Corp.) at pH 6.2. Next day cells were 
incubated with 20 mM of SNARF-5F in L-15 phenol red free media at pH 6.2 for 1 hr 
followed by washing three times with 50 mM phosphate/ citric acid solution at pH 
5.5, 6.0, 6.6, 7.2 or 7.5. Next, 25 µl of 0.4 µg/ml nigericin was added to cells and 
incubated for 15 min to equilibrate the intracellular pH with the pH of buffer. 
Fluorescent spectra of SNARF-5F before and after addition of nigericin to the cells 
were recorded in the range of 520–800 nm on a fluorescent inverted microscope 
IX71 (Olympus America, Inc.) with an attached Shamrock 303 (AndorTechnology, 
Inc.) spectrograph equipped with a Newton EMCCD (electron multiplied charged 
couple device) camera (Andor Technology, Inc.) using 480 ±10 nm excitation an 
interference filter and a long pass emission filter with 520 cutoff wavelength. Ratio 
of SNARF-5F fluorescent signal at 595 nm/640 nm were calculated for each pH and 
plotted against the respective pH, and fitted with a linear function using Origin9 
software (Origin Lab, Corp.) to obtain calibration curve. In separate experiment 
A549 cells were treated at pH 7.4 and 6.0 with 250 µM of the DOPC pHLIP-coated 
liposomes containing 0 or 10% gA and 5% pHLIP for 3 hrs followed by the addition 
of an equal volume of 20% FBS in DMEM and incubated overnight. At various days 
after the treatment cells were incubated with 60 µM SNARF-5F in 200 ml of L-15 
pH 6.2 for 1 hr, followed by washing with L-15 of pH 6.2 and recording SNARF-5F 
emission spectra. Next, nigericin was added to the cells to equilibrate pH and 
emission spectra of SNARF-5F were recorded once again. The SNARF-5F 
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emissions signal ratio of 595/640 nm was calculated and the corresponding 
intracellular pH was established using pH calibration curve. 
Intracellular Na
+ measurements 
 About 30,000 A549 cells of pH 7.4 and 50,000 A549 cells adapted to pH 6.2 were 
seeded in the collagen coated glass bottom dishes. Next day, cells were treated with 
1 mL of 250 µM lipid concentration of the DOPC liposomes with 10% gramicidin 
and 5% pHLIP (control – equal volume of PBS 7.4) in pH 6.2 and pH 7.4 DMEM 
without FBS and incubated for three hours. After 3 hours 1 ml of 20% FBS in 
DMEM medium at pH 6.2 and pH 7.4, respectively, were added and incubated until 
the experiments were performed. Next day, the treatment solution from the control 
and treated dishes was removed and 100 µl of 100 µM CoroNaTM Green AM 
solution in L-15 at pH 7.4 was added and incubated for 45 min. After 45 mins, cells 
were washed three times using PBS and imaged in L-15 at pH 6.2 or pH 7.4 using 
green channel of the fluorescent microscope. The same procedure was repeated with 
the treated and control cells on 3rd day after the treatment. 
Quantification of the fluorescent signals from the cells was performed using an 
ImageProPlus software. Statistical analysis of the data was performed using the 
‘‘Statistica 5.0’’ package. The p-level was computed based on the two-tailed test. 
Mitochondria depolarization assay 
 About 30,000 A549 cells were seeded in the collagen coated glass bottom dishes. 
Next day, cells were treated at pH 7.4 and 6.2 with 1 mL of 250 µM lipid 
concentration the DOPC pHLIP-coated liposomes containing 10% gA and 5% 
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pHLIP for 3 hrs followed by addition of an equal volume of DMEM containing 20% 
FBS at corresponding pH. At various days after the treatment cells were incubated 
with 10 µg/mL JC-9 solution in L-15 at pH 7.4 or 6.2 for 15 min followed washing 
and imaging. Imaging was performed on a fluorescent inverted microscope IX71 
(Olympus America, Inc.) using color Q-Color3 CCD camera (Olympus America, 
Inc.). The following excitation and emission filters were used: for green channel 490 
± 10 and 520 ± 10 nm; and for yellow channel 540 ± 10 and 580 ± 10 nm. 
Quantification of fluorescent signals from the cells was performed using an 
ImageProPlus software. Statistical analysis of the data was performed using the 
‘‘Statistica 5.0’’ package. The p-level was computed based on the two-tailed test. 
Results 
Preparation of liposomes and biophysical studies 
We introduced pH-sensitive fusogenic liposomes containing 80 mol% of DOPC 
lipids, 5% of DSPE-maleimide lipids conjugated with Cys residue at the N-
terminus of pHLIP peptide 
(ACEQNPIYWARYADWLFTTPLLLLDLALLVDADEGT), 5% of fluorescein 
(FITC) labeled lipids and 10% of gramicidin (gA: formyl-(L)W-(D)G-(L)A-(D)L-
(L)A-(D)V-(L)V-(D)V-(L)W-(D)L-(L)W-(D)L-(L)W-(D)L-(L)W-
ethanolamine) (Figure 1a). The DOPC pHLIP-coated liposomes containing gA 
formed single lamellar structures of the average size of about 120 nm in 
diameter (the polidespersity 0.07 ± 0.01 and zeta potential -230.7 ± 1.8 mV), 
which were stable within a month if kept at 4℃ (Figure 1a, b SI). The liposome 
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surface was stabilized by the negatively charged pHLIP peptides. Our previous 
data indicate that one pHLIP molecule in its extended configuration can occupy 
about 120 lipids at pH 8[17]. Thus, 5% of pHLIP in liposome (about 3% on the 
outer surface) should fully cover liposome surface. Control liposomes 
containing gA, but no pHLIP and containing pHLIP, but no gA were also tested. 
Gramicidin A is a linear peptide spanning just half bilayer and capable of 
adopting different configurations. Single stranded helical form, when two 
monomers of gA located   within inner and outer leaflets of bilayer form head-to-
head dimer, corresponds to the channel (pore) configuration of 4–5  A˚  in   the 
diameter (Figure 1b). Gramicidin in the channel configuration exhibits 
characteristic circular dichroism (CD) signal and short wavelength shift of 
the tryptophan fluorescence spectrum[18], monitored by us and shown on 
Figure 2a and Figure 2b, respectively. To demonstrate conductance of 
protons by the gA channel we performed kinetics measurements on 
liposomes containing 2% DHPE lipids head groups of which were labeled 
with FITC. The FITC carries two negative charges at pH 9. As the pH is 
lowered the carboxyl groups of FITC are protonated and FITC is transferred to 
the non-fluorescent non-charged form. Thus, decrease of pH from 9 to 3 is 
associated with the decreased of fluorescence. The pH 8 → 3 transition was 
induced by fast mixing (5 ms dead time) of the DOPC-FITC liposomes and HCl 
in the stopped-flow apparatus. The sudden decrease of about 75% of fluorescent 
signal was associated with the quenching of emission of FITC on the outer leaflet 
of bilayer. The quenching was completed within a dead time (5 ms) followed by 
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the slow kinetics reflected penetration of the protons across a bilayer. It led to 
the quenching of fluorescence of FITC located at the inner leaflet of bilayer (red 
line on Figure 2c). The data are in an accordance with the previously published 
results[19, 20]. At the same time, when 2% or 10% of gA was incorporated into 
liposomes the decrease of FITC fluorescence was completed within less than 5 
ms due to the conductance of protons by the gA channel (blue line on Figure 
2c). We also followed pH equilibration after the addition of base to induce pH 3 
→ 8 transition, which leads to the increase of FITC fluorescence. For the 
liposomes containing gA the changes of fluorescence were completed within 
less than 5 ms. At the same time, the slow kinetics was observed for the liposomes 
containing no gA (Figure 2d). 
Inhibition of cell proliferation 
Biophysical studies indicated that gA is adopting conductive channel form in the 
liposomes. The main question we proposed to answer if the pHLIP-coated 
liposomes will be able to transfer gA channel to the cellular membranes of 
cancer cells, destroy ion balance and induce cell death. All experiments were 
carried out on the cancer cells growing in standard DMEM media pH7.4 and on the 
cells adapted for low pH growth of 6.2 in DMEM. First, we tested ability of the 
pHLIP-coated liposomes containing 5 and 10% gA to inhibit proliferation of A549 
lung carcinoma cells adapted for low pH growth (Figure 2a SI). Cells were treated 
at pH 6.2 with the constructs for four days. The liposomes containing 10% gA were 
more effective in inhibition of cell proliferation, since increase of the gA 
concentration in membrane significantly raise the probability of assembling of 
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conductive channel, when both monomers come toge- ther and form head-to-head 
b-helix. The liposome composition containing 10% gA was selected for further 
experiments. A549 (human lung carcinoma), HeLa (human  cervix  
adenocarcinoma)  and M4A4 (human breast ductal carcinoma) cell lines were 
treated with the pHLIP-coated liposomes containing 10% gA and 5% pHLIP for 18 
hrs at pH 7.4 or pH 6.2 in DMEM followed by the replacement of media with 
DMEM containing 10% FBS. MTS assay was performed on 4-th day after the 
treatment to establish number of viable cells (Figure 3a–c). More than 80% of cells 
were dead in the result of treatment with the liposomes of 10 mM of total lipid 
concentration at pH 6.2. At the same time, the treatment  of cells with the same 
construct at pH 7.4 did not affect cell proliferation, except of M4A4 cells at the 
highest concentration of the construct. We also treated A549 cells for 1 day in 
DMEM of pH6.2 and then transferred cells into the pH7.4 DMEM with 10% FBS 
(Figure 3c). When cells treated at low pH were transferred to normal pH the 
cytotoxic effect was significantly less. In a control experiment, the same cell lines 
were treated at the same conditions with the pHLIP- coated liposomes with no gA 
at concentrations up to 100 µM at both pHs and no any effect on cell proliferation 
was observed (Figure 2c–d   SI). 
 No inhibition of A549 cells proliferation was also observed, when cells were 
treated for 4 days with the liposomes containing 10% gA and no pHLIP at 
concentration of up to 500 µM at both pHs (Figure 2b SI). Thus to induce 
inhibition of cell proliferation the liposomes need to be i) coated with pHLIP, 
ii) contain gramicidin channels and iii) incubated with cells at low pH. The 
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kinetics of inhibition of proliferation of A549 cells treated with the pHLIP- 
coated liposomes containing 10% gA at pH 6.2 was monitored by the changes 
of capacitance measured at AC frequencies using the electric cell-substrate 
impedance sensing (ECIS) technique (Figure 3d). The capacitance varies in a 
linear fashion with the fractional cell coverage of the bottom of special chamber 
coated with the thin film gold electrodes connect to the ECIS electronics[21]. 
When cells were shrinking and dying after the treatment with the construct the 
capacitance was increasing. The cell death happens couple days after the 
treatment. 
Acidification of intracellular space 
 We assumed that the pHLIP- coated liposomes fuse with the cellular membrane 
and deliver gA channels to the plasma membrane. The efficient conductance of 
protons of gA channel from the extracellular space to cytoplasm leads to the 
acidification of intracellular space. The pH-sensitive fluorescent dye SNARF 
was used to measure pH in a cell[22]. SNARF in the ester form can freely diffuse 
across the membrane into cytoplasm, where in the result of esterification it is 
transferred to the cell-impermeable fluorescent carboxyl acid. Fluorescence of 
carboxy SNARF at 595 nm increases with pH changes from 8 to 5. Fluorescent 
spectra from the cells (Figure 4a) were recorded using an Andor spectrometer 
coupled with a fluorescent microscope. Nigericin, K+/H+ ionophore, was used 
to disrupt balance of the protons and equilibrate pH between the extracellular and 
intracellular spaces, which was needed for the calibration of the fluorescent signal 
of SNARF in cells[23]. Ratio of SNARF fluorescent signals at 595 nm to 640 nm 
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were calculated for each pH and plotted against the respective pH, which 
allowed constructing the calibration curve (Figure 4b). Then, fluorescent signal 
of SNARF was measured in A549 cells treated with the pHLIP-coated 
liposomes containing 10% gA and non-treated cells. First day after the 
treatment, the pH inside the non-treated (control) and treated cells was 7.08 and 
7.02, respectively (Figure 4b, blue and magenta circles). However, on the second 
day after the cells treatment the intracellular pH was dropped to 6.53 (Figure 4b, 
red circle), while the intracellular pH in the control group was around 7.23 (Figure 
4b, green circle). After each measurement of intracellular pH, the nigericin was 
added to the cells, and the measured pH was found to be around 6.2–6.3 in each 
case as expected, as a pH of L-15 media used in the experiment. 
Disruption of cellular balance of Na+ ions 
 It is known that gramicidin pore conducts well not only protons, but all 
monovalent cations including sodium and potassium ions. We used sodium ion 
indicator, CoroNa Green dye, that exhibits an increase in green fluorescence  
upon  binding  Na+    in  presence  of    physiological concentrations of other 
monovalent ions[24, 25]. A549 cells non-treated and treated with the pHLIP-
coated liposomes containing 10% gA at both 7.4 and 6.2 pHs were loaded at 
different time points with the cell-permeable CoroNa Green AM, washed and 
imaged. We observed enhancement of the green fluorescence of cells treated 
with the liposomes at low pH on day 1 and even more significant increase of 
fluorescence on day3 (Figures 5). It indicates the equilibration of concentration 
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of sodium ions in the extracellular and intracellular spaces in the result of 
transfer of sodium ions into the cytoplasm via the gramicidin channel. 
Mitochondria depolarization assay 
 Disturbance of the balance of monovalent ions and acidification of the 
intracellular space induces apoptosis, which was monitored by the 
depolarization of mitochondria. Membrane-permeable dye, JC-9, exhibits 
potential- dependent accumulation in the mitochondria monitored by the  
fluorescence emission shift from green (~530 nm) to orange (~590 
nm)[26]. Consequently, the mitochondrial depolarization is reflected by 
increase in the green/orange fluorescence intensity ratio (Figures 6). The ratio 
of green/orange fluorescence of   JC-9 dye was measured on the A549 cells at 
different time points after cells treatment at both pHs of 7.4 and 6.2 with the 
pHLIP-coated liposomes containing 10% gA and on non-treated cells. Only 
cells treated with the liposomes at low pH demonstrate increase of green/ orange 
fluorescence ratio at 3-rd and 4-th days after the treatment indicating to the 
mitochondria depolarization and cell apoptosis. 
Discussion 
The pHLIP-coated liposomes mimic highly efficient intracellular delivery 
systems utilized by the viruses and pathogenic organ- isms[27-29], since pHLIP 
at low pH performs function of the fusogenic peptides that brings membrane of 
the liposome and a cell in close contact[16]. There are two case scenarios: i) the 
liposome membrane fuse with the cellular membrane and transfer gramicidin 
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conductive channel to the plasma membrane, or ii) the liposome enters a cell via 
endocytosis, most probably, macropinocytosis, in the result of simultaneous 
insertion of several pHLIP peptides into the plasma mem- brane, which can lead 
to the plasma membrane raffling and blebbing and can trigger internalization of 
the liposomes (Figure 7). In the latter case, the pHLIP-coated liposome will fuse 
with the membrane of endosome at low pH. In both case scenarios, the gramicidin 
channels will disrupt the balance of monovalent cations. At the same time, proton 
pumps and sodium/potassium ion channels actively pump protons and sodium 
ions from the cytoplasm to the extracellular space and potassium ions to the 
cytoplasm. It takes time for complete equilibration of ions. Disturbance of ion 
balance leads to the mitochondria depolarization, which is a signal of early 
apoptosis. Interestingly, cells treated for 1 day at low pH with the pHLIP-coated 
liposomes containing gramicidin, but then transferred to the media of normal 
pH, demonstrated much less cytotoxicity compare with the cells growing at low 
pH all the time. 
We already demonstrated the pHLIP-mediated delivery and accumulation of 
optical, PET and SPECT imaging agents, gold-nanoparticles and liposomes to 
the acidic diseased tissue[10, 12, 13, 15].  
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Figures 
 
Figure 1. Schematic presentation of lipid bilayer of the pHLIP-coated 
liposomes containing gramicidin A (gA) ion-conductive channels (a). Top view 
of the gA channel showing conductive pore of 5 A˚ in the diameter (the atomic 
coordinates of gA were visualized by the RasWin Molecular Graphics program using 
1 MAG file from the Protein Data Bank). 
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Figure 2. Biophysical characterization of liposomes containing gramicidin A. The 
circular dichroism (a) and tryptophan fluorescence (b) of the DOPC liposomes 
containing 10% gA were are shown (c–d) The DOPC liposomes containing 2% FITC-
DHPE lipids and containing no gA (red line) or 2% gA (blue line) in phosphate buffer 
pH 8 or pH 3 were mixed with HCl or NaOH (dead time of mixing was 5 ms) to induce 
transition from pH 8 to 3 (c) or transition from pH 3 to 8 (d), respectively. The changes 
of FITC emission were observed in real time in the stopped- flow apparatus. The 
baseline signal obtained by mixing of liposomes at pH 8 or pH 3 with buffer of the same 
pH is shown by black lines. 
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Figure 3. Inhibition of cell proliferation. HeLa, human cervix adenocarcinoma, 
(a), M4A4, human breast ductal carcinoma, (b), A549, human lung carcinoma (c) 
cells grown in standard media of pH 7.4 and adapted for low pH growth of 6.2 were 
treated with the DOPC pHLIP- coated liposomes containing 10% gA and 5% pHLIP 
for 18 hrs at pH 7.4 or 6.2 in DMEM followed by the replacement of media with 
DMEM containing 10% FBS of the same pH as treatment or DMEM of pH7.4, 10% 
FBS (blue columns). MTS assay was performed on 4-th day after the treatment. 
(d) About 25,000 of A549 cells were seeded in an 8W10E 1 ECIS array in 
DMEM at pH 6.2, next day cells were treated for 3 hrs with different 
concentrations of the DOPC pHLIP-coated liposomes containing 10% gA and 5% 
pHLIP liposomes in DMEM at pH 6.0 followed by addition an equal volume of 
the DMEM containing 20% FBS at pH 6.2. The kinetics of inhibition of cell 
proliferation was monitored by changes of capacitance within 5 days. 
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Figure 4. Monitoring changes of intracellular pH. First, calibration curve was 
established: A549 cells grown at pH6.2 were incubated with SNARF-5F 
followed by washing with 50 mM phosphate/citric acid solution of pH 5.5, 6.0, 
6.6, 7.2 and 7.5. To equilibrate extracellular and intracellular pH, the ionophore 
nigericin was added to cells and the fluorescence spectra of SNARF-5F were 
recorded (a). Ratio (595/640 nm) of SNARF-5F fluorescent signal was plotted 
for each respective pH (black dots) and the linear fit was performed to establish 
calibration curve (b). The fluorescence spectra of SNARF-5F was obtained on 
A549 cells non-treated and treated with the DOPC pHLIP-coated liposomes 
containing 10% gA and 5% pHLIP at pH 7.4 or 6.2 for 3 hrs followed by addition 
an equal volume of the DMEM containing 20% FBS. The SNARF-5F emission 
ratio of 595/640 nm was calculated and the corresponding intracellular pH was 
obtained from the pH calibration curve (color dots on panel   b). 
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Figure 5. Monitoring changes of intracellular concentration of Na+. A549 cells 
non-treated or treated for 1 day with the DOPC liposomes with 10% gramicidin 
and 5% pHLIP at pH 6.2 and pH 7.4 were incubated with CoroNaTM Green next 
and 3-rd days after the treatment followed by washing and imaging of cells. The 
representative fluorescent and phase-contrast images of cells are shown (a–d). 
The average per cell fluorescence intensity changes for control and treated cells 
are shown on panel e. 
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Figure 6.  Mitochondria depolarization assay. The representative fluorescent JC-
9 images of A549 cells non-treated and treated with the DOPC pHLIP- coated 
liposomes containing 10% gA and 5% pHLIP at pH 7.4 and 6.2 are shown (a–d). 
Depolarization of mitochondria is characterized by changing color from yellow to 
green of JC-9 fluorescence. The cells images were taken at excitation and emission 
wavelengths centered at 490 nm and at 520 nm (green) or 540 nm and 580 nm 
(yellow), respectively, at different days after cells treatment with the liposomes. The 
changes in average ratio of green to yellow signals are shown on panel e. 
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Figure 7.  Schematic presentation of interactions of lipid bilayer of the pHLIP-
coated liposomes containing gA with plasma membrane of a cell., which leads to the 
transferring of gA channels (nano-pores) to the cellular membranes and disruption of 
the monovalent cations balance (presentation of liposome in the endosome is schematic 
and not in a   scale). 
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Figure 1 SI. a) Size and Zeta Potential of pHLIP coated gA liposomes. Cryo-TEM 
image of the DOPC pHLIP-coated liposomes containing 10% gA at 40,000x 
magnification. b) Diameter and zeta potential of the DOPC pHLIP-coated liposomes 
containing 10% gA, which were kept at 4℃ in 10 mM phosphate, 150 mM NaCl, pH 
7.4 buffer, were monitored within 30 days. 
 
a 
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Figure 2 SI. Control experiments a) A549 cells adapted for low pH growth were 
treated for 3 hrs with the DOPC pHLIP-coated liposomes containing 5% pHLIP and 0-
10% gA in DMEM at pH 6.2 followed by the addition of an equal volume of the DMEM 
with 20% FBS. MTS assay was performed on 4-th day after the treatment. b) about 
3,000-4,000 A549 cells grown at pH 7.4 and 6.2, respectively, were treated with the 
DOPC liposomes containing 10% gA, but no pHLIP for 18 hrs in DMEM at pH 7.4 or 
6.2 followed by the replacement of media with DMEM containing 10% FBS. MTS 
assay was performed on 4-th day after the treatment. c-d) about 3,00-4,000 A549 cells 
grown at pH 7.4 and 6.2, respectively, were treated with the DOPC pHLIP-coated 
liposomes containing 5% pHLIP, but no gA for 18 hrs in DMEM at pH 7.4 or 6.2 
followed by the replacement of media with the DMEM containing 10% FBS. MTS assay 
was performed on 4-th day after the treatment.       
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Abstract 
Currently, nanomedicine is becoming very popular over conventional methods due to 
the tunable physico-chemical properties used as successful therapeutic and diagnostic 
agents to treat cancer and many other pathogenic conditions. However, the success of 
these nanomedicines primarily relies on how specifically and efficiently they can target 
pathological sites by minimizing undesirable effects. Here, we propose a novel class of 
targeted nano- drug delivery system, which can be used as an effective nano-theranostic 
for cancer. We formulated small, unilamillar niosomes using non-ionic surfactants 
(SPAN20), cholesterol and pH(Low) Insertion Peptide (pHLIP), which is our targeting 
moiety. pHLIP coated niosomes can sense the extracellular acidity of cancerous cells 
and at low pH they can insert into the cellular membrane and successfully deliver 
niosomes carrying hydrophobic or hydrophilic agents into the cells. Intravenous 
injection of pHLIP-coated, noisome constructs show remarkable accumulation in mice 
tumors compared to their pH- insensitive noisome constructs. Long circulation time and 
uniform bio-distribution throughout the entire tumor and cells make them better delivery 
systems for future clinical applications. 
 
Keywords: pHLIP, niosomes, drug delivery, tumor acidity, targeted therapy, 
nanomedicine  
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Introduction 
At present, scientists from various disciplines all over the world are involved in the 
study of vesicles and other colloidal structures as carriers for passive or active targeting 
to improve cancer therapy. However, most of the currently approved nanomedicinal 
products for cancer therapy are non-targeted nanovectors that accumulate in tumor 
tissues purely through the enhanced permeability and retention (EPR) effect and release 
their payload in the extravascular tumor tissues for antitumor efficacy [1]. It is nearly 
impossible to find a universal active targeting moiety for cancer as it is essentially 
heterogeneous in nature[2, 3]. However, the extracelluar acidity of tumor cells has been 
identified as a general property of cancerous cells and thus it can be used as a hallmark 
to target tumors[4, 5]. Since a little over a decade ago when pH(Low) Insertion Peptide 
(pHLIP) was discovered, this remarkable peptide has become a perfect candidate for 
this purpose [6, 7]. This pH sensitive peptide stays in monomeric and unstructured form 
in solution at normal pH in the absence of the lipid membrane. At the presence of the 
lipid membrane, it binds to the surface, and, mainly, it stays as an unstructured 
monomer. But at low pH, the Asp and Glu residues of the peptide protonate and enhance 
its hydrophobicity causing it to insert into the cellular membrane by forming an apla -
helix [8, 9]. By appropriately modifying its N- or C- terminus, pHLIP can be used as a 
bio-marker or it can be used to deliver membrane impermeable cargo into the cell by 
utilizing the energy released during its insertion process[10-12].  It has also shed new 
light on targeted nanomedicine since pHLIP has repeatedly proven its ability to sense 
extracellular acidity over a wide variety of applications. Therefore, since the discovery 
of pHLIP technology, various research groups have been applying this technology to 
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form pH-sensitive nanoparticles based on lipid and inorganic materials[13-17]. In this 
study we show how we can use pHLIP technology to formulate pH-sensitive, fusogenic 
niosomes for cancer therapy.    
Niosomes are closed bilayer structures formed by the self-assembly of non-ionic 
amphiphiles in aqueous media. They were initially developed and patented by the 
cosmetic company L’Oreal in the late 1970s [18], and the first commercial product of 
“Niosome” antiaging cream was introduced to the market in the 1980s. They are 
analogous to liposomes; like liposomes, niosomes can be multilamellar or unilamellar 
vesicles, able to encapsulate both hydrophilic and lipophilic drugs. Non-ionic surfactant 
vesicles are osmotically active, chemically stable, and have long shelf lives compared 
to liposomes. Different types of surfactants have been proposed as starting materials 
such as the Span® series, Tween® series and the Brij® series  to prepare niosomes[19]. 
Physical and chemical properties of these surfactant families can be utilized to achieve   
stable vesicular carriers, which have influence on  fluidity, microviscosity and polarity 
of bilayers [20-23]. 
Sorbitan esters (Spans®) are FDA approved for use in food processing and 
pharmaceuticals [24].  They are safe, amphiphilic compounds derived from sorbitol 
(i.e., a synthetic sweetener). Sorbitan esters are prepared by controlled dehydration 
of sorbitol followed by lipase-catalyzed esterification of the resulting sorbitan. 
Vesicles prepared by Span-series surfactants have been reported to be viable drug 
carriers for different diseases and for different routes of administration (about 100 
articles published in the last 5 years – data retrieved from Scopus).  
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Span 20 consists of a fully saturated short alkyl chain (lauryl - C12). The single carbon 
bonds in Span 20 allow the alkyl chain to pack tightly, resulting in a rigid membrane 
for the assembled niosomes. According to this, Span 20 seems to assemble into smaller 
and most stable niosomes compared to Span 40 and Span 60, which bear long saturated 
acyl chains [palmityl (C-16) and stearyl (C-18) chains respectively] [25]. It was reported 
that the length of alkyl chain is a crucial factor of permeability [26].Furthermore, Span 
40 and 60 are in a gel state, compared with a liquid surfactant at room temperature. Such 
features render Span 40- and Span 60-based niosomes less likely to leak the 
encapsulated water-soluble drug molecules into their surrounding solution. In contrast, 
Span 20-based niosomes are fluid at room temperature [27].  
 
Materials and Methods 
Materials 
Sorbitan monolaurate (SPAN20) ,Cholesterol ≥ 99%, N-(2-Hydroxyethyl)piperazine-
N′-(2-ethanesulfonic acid) (HEPES) ≥ 99.5%(titration) & N-(1-Pyrenyl)maleimide 
(Pyr-maleimide)  were purchased from  Sigma-Aldrich Inc (Atlanta, GA). 1,2-dioleoyl-
sn-glycero-3-phosphoethanolamine-N-[4-(p-maleimidophenyl)butyramide] (sodium 
salt) (DSPE-maleimide), were obtained from Avanti Polar Lipids (Alabaster, AL). 
Octadecyl Rhodamine B Chloride (R18) was purchased from  Thermo Fisher Scientific 
Inc. The wild type pH(Low) Insertion Peptide 
(ACEQNPIYWARYADWLFTTPLLLLDLALLVDADEGT) was prepared by solid-
phase peptide synthesis at C.S.Bio, CA and hereafter it will be referred as WT. All other 
chemicals used were of the highest purity available and solvents were of spectroscopic 
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grade. Water was purified through a Millipore(Bedford, MA) Milli-Q system and used 
for all experiments.  
Synthesis of DSPE-WT pHLIP & Pyr- WT pHLIP 
DSPE-WT and Pyr-WT were synthesized by the covalent conjugation of malemide head 
group of DSPE and Pyrene with the single cysteine residue at the N-terminus of WT . 
The reaction was done with peptide to maleimide molar ratio 1.1:1  in Methanol and left 
for overnight stirring at room temperature under argon. The existence of the product 
was ensured by SELDI-TOF mass-spectrometry analysis. 
SPAN-20 niosome preparation 
10 mM stock solutions of SPAN20 and cholesterol were prepared by dissolving the 
products in chloroform & methanol mixture of 3:1 (v/v).  Solutions of the 43–50 mol% 
of SPAN20, 50 mol% cholesterol mixed with 5 mol% DSPE-WT or Pyr-WT  and 2 
mol% fluorescent dye (R-18) were evaporated using a rotary evaporator at 60 °C 
producing an even thin film for 1 hour, followed by the additional one hour evaporation 
under a high vacuum to remove traces of organic solvents. This layer was hydrated in 2 
mL ,10 mM, pH 7.4 HEPES buffer solution with or without 5 mM Ca2+. The resulting 
solution was sonicated using the probe sonicator for 5 minutes at 60 degrees Celsius and 
extruded 31 times through 200 nm filters. Niosomes were sterilized by filtering through 
0.2 μm filter before the addition to cells. The concentration of SPAN20 was calculated 
by measuring absorbance of R18 at 546 nm (ε = 104,126 M−1 cm−1) or pHLIP at 280 
nm (ε = 13,940 M−1 cm−1 ) of the niosomes dissolved in methanol. Niosomes were 
stored at 4°C. 
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DLS and Zeta potential measurements 
The size distribution of niosomes was measured by dynamic light scattering (DLS) 
using a Malvern Zetasizer Nano ZS instrument with Malvern disposable cuvettes 
(Malvern USA). The shelf life was monitored for a one month period in 10 mM HEPES 
buffer at pH 7.4. In addition, size measurements were taken for 20 hours in 5% (v/v) 
Serum medium at pH 7.4.  The zeta potential was measured on the same instrument 
using folded capillary cells from Malvern. 
Cryo-electron microscopy 
About 5 μL droplet of niosome solution was spread on a Lacey Formar/Carbon electron 
microscopy grid and preserved in a frozen-hydrated state by a rapid freezing in liquid 
ethane. The vitrification process was performed via FEI Vitrobot system with the setting 
of a single blot of 3 sec, an offset of 1, and drain and wait time of 1 sec. Samples were 
imaged using JEOL 2100 TEM with an accelerating voltage of 200 kV at magnifications 
of 15,000× and 25,000×. 
Cell lines 
Lung carcinoma A549 and mouse mammary metastatic cancer 4T1 cell lines were 
obtained from American Type Culture Collection (Manassas, VA). Cells were 
authenticated, stored according to supplier’s instructions, and used within 3–4 months 
after frozen aliquots resuscitations. Cells were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM) and Roswell Park Memorial Institute  Medium (RPMI) 
supplemented with 10% (v/v) fetal bovine serum, 0.1% (v/v) of 10 μg/mL of 
ciprofloxactin in a humidified atmosphere of 5% CO2 and 95% air at 37°C.  
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Cell proliferation assays 
About 3,000 of A549 and 4T1 cells were seeded in 96 well-plates at pH 7.4.  The 
following day, cells were treated for 2 hrs with various concentrations of pHLIP-coated 
niosomes in respective serum free media at pH 7.4 and followed by the addition of an 
equal volume of respective medium with 20% (v/v) FBS. For another set, the treatment 
was completely removed after 2 hours and incubated again after adding fresh 10% (v/v) 
FBS medium. Cells were grown until non-treated cells in control reached 80–90% 
confluence. Cell viability was assessed by the colorimetric reagent (CellTiter 96 
AQueousOne Solution Assay, Promega) of the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay, which was added 
for 1 hour to cells followed by measuring absorbance at 490 nm. All samples were 
prepared in triplicate. Each experiment was repeated several times. 
Measurement of cellular uptake 
A549 and 4T1 cells in suspension were treated with R-18 labelled niosomes at low & 
high pH for about 1 hour. After washing, cellular uptake of fluorescent niosomes was 
assessed by the counting of fluorescent cells on a cellometer before and after adding 
trypan blue. All data were normalized to the fluorescent intensity of 4T1 cells treated at 
pH 7.8 with DSPE-pHLIP. After washing, another set of suspended cells were seeded 
on collagen-coated dishes and the following day the light and fluorescent images were 
taken for low pH treated cells for qualitative purpose. 
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Tumor Mouse Models 
All animal studies were conducted according to the animal protocol AN04-12-011 
approved by the Institutional Animal Care and Use Committee at the University of 
Rhode Island, in compliance with the principles and procedures outlined by NIH for the 
Care and Use of Animals. 4T1 mammary tumors were established by subcutaneous 
injection of 4T1 cells (1 × 106 cells/mL ,0.1 mL/flank) in the right flank of adult female 
BALB/c mice (about 19–22 g weight) obtained from Harlan Laboratories.  
Fluorescence Imaging of Organs 
When 4T1 tumors reached 6-9 mm in diameter, they were intravenously injected with 
different constructs of niosomes contained R18 (100 µL of 50 µM) via the tail vein.  At 
4 h, 24 h & 48 h from post injection the mice were euthanized and organs were harvested 
and imaged using FX Kodak image station and mean fluorescence intensities of tumor 
and organs was calculated using ImageJ software.     
Imaging of Tumor Sections 
Frozen tumor tissues were sectioned at a thickness of 5 μm using a Vibratome UltraPro 
5000 Cryostat. Sections were mounted on microscope slides, dried in air, and washed 
with deionized water. Tumor sections with the R18 contained pHLIP niosomes were 
analyzed without further processing using Zeiss LSM 700 confocal module under DAPI 
and Rhodamine channel at 20x magnification.  Following fluorescence imaging, the 
adjacent sections were then stained with hematoxylin and eosin (H&E) and imaged 20x 
magnifications. 
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Ca2+ Experiments: Cytotoxicity Assays and  ECIS 
About 3,000 4T1 cells were seeded in 96 well-plates at pH 7.4.  The following day, cells 
were treated for 3 hrs with various concentrations of Pyr-WT-coated niosomes 
containing 5 mM Ca2+  in RPMI serum free media at pH 7.4 and pH 6.5. After 3h, the 
treatment was completely removed and incubated again after adding fresh 10% (v/v) 
FBS medium at pH 7.4. Cells were grown until non-treated cells in control reached 80–
90% confluence. Control assay was run with the treatment niosomes without Pyr-WT. 
Cell viability was assessed by the colorimetric reagent (CellTiter 96 AQueousOne 
Solution Assay, Promega) of the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay, which was added 
for 1 hour to cells followed by measuring absorbance at 490 nm. All samples were 
prepared in triplicate. Each experiment was repeated several times. 
The kinetics of inhibition of proliferation of 4T1 cells treated with pyr-WT coated 
niosomes containing 5 mM Ca2+ HEPES physiological medium was monitored by 
changes of capacitance measured at AC frequencies using the ECIS (electric cell-
substrate impedance sensing) technique. The capacitance varies in a linear fashion with 
the fractional cell coverage of the bottom of a special chamber coated with thin film 
gold electrodes connect to the ECIS electronics[28]. When cells were shrinking and 
dying after treatment with the construct the capacitance was increasing. The cell death 
starts within 30 minutes after the treatment.  
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Ca2+ Experiments: In Vivo Studies 
4T1 mammary tumors were established by subcutaneous injection of 4T1 cells (1 × 106 
cells/mL ,0.1 mL/flank) in  both flanks for the IT injection group and only in the right 
flank for the IV injection group of adult female BALB/c mice (about 19–22 g weight) 
obtained from Harlan Laboratories. When tumors became visible, 50 uL and 150 µL, 
2.5 mM Pyr-WT niosomes with 5 mM Ca2+ were injected into the mice directly into the 
tumor and via the tail vein respectively. The injections were performed for three 
consecutive days for both IT and IV groups. The control was not given any injection. 
On the 5th day from the initial injection, mice were euthanized and tumors were 
harvested and weighed.    
Results 
We were able to formulate very stable niosomes with the average hydrodynamic size of 
~80 nm (Fig. 1, Table 1) and they showed a prolonged shelf life at 4 °C in 10 mM 
HEPES buffer at pH7.4 (SI .Fig 1). At this pH, anionic pHLIP adds electrostatic 
repulsion to the niosomes. In addition to that, 5% pHLIP, which is more than enough to 
cover the noisome surface completely, could act as grafted polymers, sticking out into 
the solution. When the particles come close enough to overlap, the local increase of 
polymer concentration leads to an osmotic pressure, causing a repulsive force which 
further minimizes inter-niosomal fusion. Due to these effects, we observed high zeta 
potential for the niosomes showing high stability over an extended period at 4 °C. 
Cell proliferation assays done with 4T1 & A549 cells confirmed that DSPE-WT pHLIP 
and Pyr-WT pHLIP-coated niosomes do not show any toxicity for the surfactant 
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concentration up to 1 mM ( SI Fig 2).  The cellular uptake of pHLIP-coated niosomes 
were monitored using R18 fluorescence. It is evident that at low pH, significantly high 
cellular uptake occurs compared to cells treated at high pH (Fig.a, b, c & d) . After 
adding trypan blue, the fluorescent signal of R18 was remeasured for each pH and cell 
line to ensure the signal came only from the R18 within the cell. This data also confirms 
that at low pH there is higher uptake of pHLIP labelled niosomes (Fig 2, SI.Fig 3). 
Fluorescent images taken at low pH for both constructs and for both cell lines clearly 
show the distribution of R18-labeled niosomes over the cellular membranes and 
throughout the cell (Fig.2 a,b,c & d). This data confirms that the pH-dependent and 
mediated cellular uptake of pHLIP coated niosomes. 
In-vivo kinetics (Fig 3) show a higher accumulation of both the DSPE-WT and Pyr-WT 
niosomes in tumor sites 24 hours post injection compared to other organs. The R18 
intensity profile for the same organs (Fig 4 a,b) were analyzed after 24 hours from I.V. 
administration of DSPE-PEG, DSPE-WT pHLIP, DSPE-6K, Pyr-WT  and Pyr-6K  
constructs. Here, 6K stands for the pH independent counter-part of WT pHLIP where 
all D(Asp) and E(Glu) residues were replaced by K(Lys). DSPE-PEG, DSPE- 6K, and 
Pyr- 6K show accumulation in the tumor site purely due to the EPR effect. However, 
DSPE- WT and Pyr- WT show about a two-fold accumulation compared to the other 
three constructs. Tumor sections taken from the interior of the tumors (Fig. 5) clearly 
show that both niosomes coated with DSPE –WT and Pyr-WT distributed throughout 
the tumor and fused with extra and intra cellular membranes more evenly.   
We were able to use Pyr-WT coated niosomes to deliver 5 mM Ca2+ ions to 4T1 cancer 
cells and tumors as a novel therapeutic agent. Cyto-toxicity assays done with niosomes 
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with and without Pyr-WT shows that at low pH only the Pyr-WT coated niosomes can 
inhibit the cell proliferation in a concentrated dependent manner (Fig.6). Kinetics data 
(ECIS) show that this cell death starts within 30 minutes of treatment(Fig.7). 
After 3 consecutive days of intra-tumoral injections of Pyr-WT niosomes containing 5 
mM Ca2+ , it was seen to significantly suppress the growth of tumors compared to its 
control on the 5th day. The IV injections also show that Pyr-WT coated niosomes with 
5 mM Ca2+ could suppress tumor growth (Fig 8).   
 Discussion 
The DSPE-WT and Pyr- WT coated niosomes,  follow a closely similar mechanism 
utilized by viruses and pathogenic organisms to enter into  cells [14, 15, 29, 30] . At low 
pH, pHLIP behaves as a fusogenic peptide to bring the noisome membrane and the 
extracellular membrane in close contact. There are two main possibilities for this 
cellular entry. Either the noisomes fuse directly with the extracellular membrane or they 
can be taken up into the cell via an endocytotic path, or more favorably, via 
micropinocytosis due to several simultaneous pHLIPs inserted into the membrane. 
Niosomes, which are internalized into the cell via endocytosis, will further fuse with the 
endosome membrane at low pH. In either case, niosomes modified with lipophilic or 
hydrophilic drugs can effectively enter into the cells in a pH-dependent manner.  
In-vitro studies confirm that niosomes distribute throughout the cell and the cellular 
uptake is governed by the extracellular acidicity of the cancerous cells. In vivo results 
show that the pHLIP coated niosomes possess long circulation half-life because of their 
stability, small size, and stealth properties which help niosomes to accumulate more in 
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tumor sites through the EPR effect. The tumor sections also show that the niosomes can 
distribute throughout the tumor. In addition to this, low toxicity, prolonged shelf life, 
and low manufacturing cost also make niosomes ideal targeted, drug delivery systems 
for carrying therapeutics and diagnostics to cancer.        
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Tables 
 
 
Table 1. Niosome Characterization Data Average hydrodynamic diameter and zeta 
potential of the SPAN20 niosomes containing 5% of DSPE-WT & Pyr-WT coating at 
pH 7.4 HEPES buffer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Construct Avg. 
Diameter 
(nm) 
Zeta Potential 
(mV) 
PDI 
45%SPAN20+5%DSPE-
WT+50%Cholesterol 
 
84.3 ± 0.9 -35.4 ± 2.3 0.19 ± 0.01 
45%SPAN20+5% Pyr- 
WT+50%Cholesterol 
78.5 ± 0.5 -31.3 ± 1.7 0.25 ± 0.01 
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Figures 
 
 
Figure 1: Cryo -TEM  Cryogenic TEM image of the a.) DSPE-WT and b.) Pyr-WT 
coated SPAN20 niosomes, The images are taken at HV=200.0 kV and at 25,000x 
magnification  
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Figure 2. Cellular Uptake of R18 Niosomes Fig. 2 a-d : 4T1 and A549 cells uptake of 
DSPE-WT and Pyr-WT coated SPAN20 niosomes at low pH at 40x magnification Fig. 
2 e & f: R18 fluorescent intensity per cell at high and low pH for two cell lines for before 
and after adding trypan blue. The normalization is done by the intensity of 4T1 cells at 
pH 7.8, treated with DSPE-WT (before adding trypan).    
Before Trypan 
After Trypan 
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Figure 3: In-Vivo Kinetics Time-dependent distribution of DSPE-WT and Pyr-WT 
coated R18 SPAN20 niosomes in tumor, muscle, kidney and liver at 4 h , 24 h and 48 h 
from post-injection. The net, absolute fluorescent intensity of R18 is shown.  
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b 
                                       
                                                           
Figure 4: In-Vivo Imaging 24 h Fig.4 a: Absolute net mean R18 fluorescent intensity 
by tumor, muscle, kidney and liver for five constructs after 24 h from I.V. injection. 
DSPE-6K and Pyr-6K constructs are the controls. ∗ 𝑝 ≤ 0.05 𝑎𝑛𝑑 ∗∗ 𝑝 ≤ 0.005  
Fig.4 b: Distribution of different pHLIP niosomes over tumor, muscle, kidney and 
liver.   
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Figure 5: Tumor Sections Tumor sections with the R18 contained pHLIP niosomes 
were analyzed without further processing using Zeiss LSM 700 confocal module under 
DAPI and Rhodamine channel at 20x magnification. 
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Figure 6: Delivery of Ca2+ into Cancer Cells using Pyr-WT coated niosomes. 
4T1 cells grown in standard media of pH 7.4 were treated with the pyr-pHLIP 
coated niosomes and noisome alone containing 5 mM Ca2+ HEPES buffer for 3 hours at 
pH 7.4 and 6.5. After 2 hours the treatment was completely removed and  the 
replacement of media with RPMI medium  containing 10% FBS of the pH 7.4 . 
MTS assay was performed on 2nd  day after the treatment.  
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Figure 7. ECIS Assay. About 25,000 of 4T1cells were seeded in an 8W10E 1 
ECIS array in RPMI at pH 7.4, next day cells were treated for 3 hrs with pyr-
pHLIP-coated niosomes  containing 5 mM Ca2+ HEPES physiological medium. 
Control was treated with the  5 mM Ca2+ HEPES physiological medium. After 3 
hours the treatment was completely removed and fresh RPMI medium at 7.4 was 
added, The kinetics of inhibition of cell proliferation was monitored by changes of 
capacitance within 2 days. 
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Figure 8. Delivery of Ca2+ into tumors using Pyr-WT coated niosomes. 50 µL and 
150 µL, 2.5 mM Pyr-WT niosomes with 5 mM Ca2+ were injected to mice directly into 
the tumor and via tail vein respectively. The injections were performed three 
consecutive days for both IT and IV groups. Control was not given any injection. The 
5th day from the initial injection, mice were euthanized and tumors were harvested and 
weighed.    
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Supplementary Information 
 
 Construct 
4T1 A549 
DSPE-WT Pyr-WT DSPE-WT Pyr-WT 
 pH 7.8 pH 7.8 pH 7.8 pH 7.8 
DSPE-WT pH 5.5 5.72405E-17 - 4.4094E-118 - 
Pyr-WT pH 5.5 - 3.188E-131 - 2.158E-176 
 
Table 1 SI. p-values for Cellular uptake after adding trypan blue for Fig 2 (e,f)  
 
 DSPE-PEG DSPE-WT DSPE-6K Pyr-WT Pyr-6K 
 n=3 n=3 n=3 n=3 n=3 
Tumor 1108  ±  28 2015  ±  96 859   ±  104 2409  ± 334 762   ± 102 
Muscle 209  ±  29 363   ±  25 63   ±  11 1173  ± 384 82   ± 17 
Kidney 233  ±  22 399  ±  38 115  ±  16 255  ± 22 1145  ±  15 
Liver 449  ±  42 1100  ±  141 315  ±  47 893   ± 195 379   ± 134 
 
Table 2 SI.  In-Vivo Data for 24 h post injection. R-18 Fluorescence Intensities for 
different constructs of SPAN20 niosomes for 24 hour post injection time point 
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a.) Tumor 
                 
 
 
 
b.) Muscle 
               
Construct DSPE-PEG DSPE-WT DSPE-6K Pyr-WT 
DSPE-WT 0.031788716  -  -  - 
DSPE-6K 0.041197513 0.004241393  - -  
Pyr-WT 0.176471875 0.227173591 0.142288157 -  
Pyr-6K 0.062865506 0.002848675 0.3722053 0.148297054 
 
c.) Kidney 
Construct DSPE-PEG DSPE-WT DSPE-6K Pyr-WT 
DSPE-WT 0.048451793  - -   - 
DSPE-6K 0.028163836 0.01483796 -   - 
Pyr-WT 0.593468874 0.069538949 0.018131454 -  
Pyr-6K 0.035691411 0.015410281 0.766032839 0.022063672 
 
d.) Liver 
Construct DSPE-PEG DSPE-WT DSPE-6K Pyr-WT 
DSPE-WT 0.05391268  - -  -  
DSPE-6K 0.15888622 0.034671751 -  -  
Pyr-WT 0.200977834 0.526664862 0.130616957 -  
Pyr-6K 0.950470866 0.070237338 0.625925234 0.221457553 
 
      Table 3 SI.   p-values corresponds to Table 2 
Construct DSPE-PEG DSPE-WT DSPE-6K Pyr-WT 
DSPE-WT 0.011110833  -  - -  
DSPE-6K 0.004084324 0.005930916 -   - 
Pyr-WT 0.085369064 0.440380217 0.054168579 -  
Pyr-6K 0.14182076 0.002074218 0.951904631 0.053471726 
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Figure 1 SI. Diameter and zeta potential of the pHLIP-coated nosomes containing, 
which were kept at 4 0C in HEPES pH 7.4 buffer and HEPES buffer with  5% FBS  
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Figure 2 SI.Cyto-toxicity Assays. 3000 cells at normal pHs were seeded in 96 well 
plates. Following day, plates were treated with different concentrations of niosome 
formulations in serum free media and incubated for 2 hours. For each treatment, after 2 
hours the medium was removed and added fresh medium. For another set equal volume 
of medium with 20% FBS added. When cell confluency reached 80-90% MTS assay 
was done. 
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Figure 3 SI. Cellular uptake of R-18 niosomes. 4T1 & A549 cells in suspension were 
treated with R-18 labelled niosomes at low & high pH. Cellular uptake of fluorescent 
niosomes was assessed by counting of fluorescent cells on a cellometer.  
